← Back to all trials
Recruiting
NCT07681323
Timing of ctDNA Testing in HR+/HER2- Advanced Breast Cancer
Conditions: Advanced Breast Cancer
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 400
Sponsor: Geneplus-Beijing Co. Ltd.
Location: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing
Summary
This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced hormone receptor-positive / human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer.
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed advanced breast cancer, molecular subtype HR+/HER2-
* Age ≥18 years
* Expected survival \>3 months
* Willing to undergo ctDNA testing and sign informed consent form
Exclusion Criteria:
* The subject has not signed the informed consent form.
* Pregnant or breastfeeding women.
* Other situations deemed by the investigator as unsuitable for inclusion in the study.
Source: ClinicalTrials.gov (NCT07681323). StuddyBuddy aggregates publicly available trial information.
